Nashai Biotech, LLC Release: Risks Of Breast Cancer And Heart Disease Prompts Millions Of Women To Seek Natural Alternatives To Lower Bad Cholesterol, Increase Good Cholesterol

NASHVILLE, Tenn., Oct. 7 /PRNewswire/ -- The 2004 update from the American Heart Association’s (AHA) Heart Disease and Stroke Statistics documents that over 50 million American women have borderline to high cholesterol levels, coupled with a recently published study in the Journal of the National Cancer Institute (2004: 96:1152-1160) that linked low levels of HDL or “good cholesterol” with increased risks for developing postmenopausal breast cancer, has prompted women across the country to identify natural alternatives to lower “bad” cholesterol, increase “good” cholesterol and reduce the risks of developing heart disease and breast cancer.

“The availability of TeaFlavin(R), a non-prescription green tea extract with clinical trial evidence that documents a 16% decrease in LDL, ‘bad cholesterol,’ and a 3%-4% rise in HDL, ‘good cholesterol’ is well timed,” says Jim Zhao, Ph.D. a molecular biologist and Chief Science Officer, Nashai Biotech, LLC. “An estimated 280,000 women die annually of either heart disease or breast cancer. We have responded to this situation by developing an all natural product that has clinically proven, positive effects for woman at an increased risk of developing heart disease, breast cancer or both.”

The AHA has clearly stated the relationship between high cholesterol and increased risks of heart disease. To mitigate these risks, an increasing number of women have begun to incorporate more exercise, a healthier diet and the addition of TeaFlavin(R) to their daily routine.

“TeaFlavin(R) was designed to offer women and men a non-prescription, heart-healthy alternative to lowering their cholesterol without the potential adverse effects of prescription medication,” says Dr. Zhao. “TeaFlavin(R) offers women a caffeine-free alternative for those seeking to reduce their cholesterol that does not contribute to the muscle-wasting and liver damage associated with the use of some prescription medications.”

The AHA recently announced new cholesterol guidelines that increase the number of Americans classified with having cholesterol levels that put them at “moderate to high risk” by several million. A large number of Americans are already feeling the pinch of higher prescription drug prices and this new “at risk population” may not want to add additional prescriptions to those they may already be taking. Many see TeaFlavin(R) as the natural solution.

For ordering information, please visit http://www.teaflavin.com/ or call 800-876-4332.

About Nashai Biotech, LLC

Headquartered in Nashville, Tennessee with offices in Irvine, California and Shanghai, China, Nashai Biotech (http://www.nashai.com/) produces patented, new generation formulas and ingredients based upon compelling scientific evidence. Nashai’s flagship product is TeaFlavin(R).

Nashai Biotech LLC

CONTACT: Peter Weissberg of CPRi Communications, +1-201-641-1911,ext. 22, pweissberg@cpronline.com